To provide the information your oncologist is not telling you or doesn't have the time to!
Here, we delve into the dynamic world of cutting-edge cancer treatments and therapies. Stay informed about groundbreaking advancements in cancer care, from emerging therapies to novel treatment modalities. Discover how science and technology are shaping the future of oncology, offering new hope and possibilities to those affected by cancer. Join us as we explore innovative approaches that hold the promise of brighter tomorrows for patients and their families.
Turning the Tide Against Platinum-Resistant Ovarian Cancer In the ever-evolving landscape of cancer treatment, ovarian cancer remains one of the most challenging battles. Platinum-resistant ovarian cancer, in particular, presents a formidable foe, often leaving patients and healthcare providers grappling with limited treatment options. But amidst this struggle, a beacon of hope emerges with the advent …
Unveiling a New Era in Colorectal Cancer Treatment: The Promise of KRAS G12C Inhibition Colorectal cancer stands as one of the most common and deadly forms of cancer worldwide. Despite advances in treatment, the search for more effective and targeted therapies continues. A significant breakthrough in this quest is the understanding and targeting of specific …
In the ongoing battle against cervical cancer, a ray of hope emerges with the FDA’s recent approval of a groundbreaking treatment approach. For women grappling with advanced stages of this disease, this marks a significant advancement, offering new possibilities in their treatment journey. Understanding Cervical Cancer: Cervical cancer, a malignancy arising in the cervix, presents …
If you or a loved one is battling locally advanced or metastatic urothelial cancer (la/mUC), there’s groundbreaking news to share. On December 15, 2023, the Food and Drug Administration (FDA) gave the green light to a dynamic combination of treatments: enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda). This approval is especially significant for patients ineligible for …
On December 14, 2023, the FDA gave the green light to belzutifan (Welireg, Merck & Co., Inc.), offering new hope for individuals battling advanced kidney cancer. It’s like unlocking a powerful tool after trying different strategies. Understanding Belzutifan’s Power Against Kidney Cancer Imagine your body as a bustling city with the kidneys playing the role …
On December 13, 2023, the Food and Drug Administration (FDA) achieved a significant breakthrough by granting approval to eflornithine (IWILFIN, USWM, LLC) for use in both adult and pediatric patients facing the challenges of high-risk neuroblastoma (HRNB). This groundbreaking decision marks the first-ever FDA approval of a therapy designed to reduce the risk of relapse …
In a groundbreaking move, the Food and Drug Administration (FDA) has granted approval for enzalutamide (Xtandi, Astellas Pharma US, Inc.) to address non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence. This significant development brings renewed hope for patients at high risk for metastasis. The Road to Approval: EMBARK Trial Insights In the EMBARK clinical trial …
The latest development in breast cancer treatment brings hope and progress. On November 16, 2023, the Food and Drug Administration (FDA) approved capivasertib, in combination with fulvestrant, for adult patients battling hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This approval marks a significant step forward for …
by Sajeve Thomas, MD, Oncologist Biliary tract cancer (BTC), a rare and aggressive form of cancer affecting the bile ducts, gallbladder, and liver, has historically been challenging to treat. However, there is hope on the horizon with the recent FDA approval of pembrolizumab (Keytruda, Merck) in combination with chemotherapy. This groundbreaking development offers new possibilities …
On November 7, 2023, the Food and Drug Administration (FDA) made significant updates to the existing indication of pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. These changes come as part of the FDA’s commitment to advancing cancer treatment options, bringing …